Cytheris Receives €1.5M Loan for HCV Clinical Development
BioWorld International Correspondent
PARIS - Cytheris SA has received a €1.5 million (US$2.3 million) interest-free loan from OSEO, France's national industrial innovation agency, to support its continuing clinical development program in hepatitis C (HCV).
The funds will enable Paris-based Cytheris to push ahead with the development of its lead product, recombinant human Interleukin-7 (r-hIL-7), a critical growth factor for immune T-cell recovery and enhancement.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter